Literature DB >> 28473464

Alterations in 3-Hydroxyisobutyrate and FGF21 Metabolism Are Associated With Protein Ingestion-Induced Insulin Resistance.

Lydia-Ann L S Harris1, Gordon I Smith1, Bruce W Patterson1, Raja S Ramaswamy1, Adewole L Okunade1, Shannon C Kelly1, Lane C Porter1, Samuel Klein1, Jun Yoshino1, Bettina Mittendorfer2.   

Abstract

Systemic hyperaminoacidemia, induced by either intravenous amino acid infusion or protein ingestion, reduces insulin-stimulated glucose disposal. Studies of mice suggest that the valine metabolite 3-hydroxyisobutyrate (3-HIB), fibroblast growth factor 21 (FGF21), adiponectin, and nonesterified fatty acids (NEFAs) may be involved in amino acid-mediated insulin resistance. We therefore measured in 30 women the rate of glucose disposal, and plasma 3-HIB, FGF21, adiponectin, and NEFA concentrations, under basal conditions and during a hyperinsulinemic-euglycemic clamp procedure (HECP), with and without concomitant ingestion of protein (n = 15) or an amount of leucine that matched the amount of protein (n = 15). We found that during the HECP without protein or leucine ingestion, the grand mean ± SEM plasma 3-HIB concentration decreased (from 35 ± 2 to 14 ± 1 µmol/L) and the grand median [quartiles] FGF21 concentration increased (from 178 [116, 217] to 509 [340, 648] pg/mL). Ingestion of protein, but not leucine, decreased insulin-stimulated glucose disposal (P < 0.05) and prevented both the HECP-mediated decrease in 3-HIB and increase in FGF21 concentration in plasma. Neither protein nor leucine ingestion altered plasma adiponectin or NEFA concentrations. These findings suggest that 3-HIB and FGF21 might be involved in protein-mediated insulin resistance in humans.
© 2017 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28473464      PMCID: PMC5482083          DOI: 10.2337/db16-1475

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  50 in total

1.  Biomarker-calibrated dietary energy and protein intake associations with diabetes risk among postmenopausal women from the Women's Health Initiative.

Authors:  Lesley F Tinker; Gloria E Sarto; Barbara V Howard; Ying Huang; Marian L Neuhouser; Yasmin Mossavar-Rahmani; Jeannette M Beasley; Karen L Margolis; Charles B Eaton; Lawrence S Phillips; Ross L Prentice
Journal:  Am J Clin Nutr       Date:  2011-11-09       Impact factor: 7.045

Review 2.  Role of insulin in the regulation of human skeletal muscle protein synthesis and breakdown: a systematic review and meta-analysis.

Authors:  Haitham Abdulla; Kenneth Smith; Philip J Atherton; Iskandar Idris
Journal:  Diabetologia       Date:  2015-09-24       Impact factor: 10.122

3.  Glucagon and Insulin Cooperatively Stimulate Fibroblast Growth Factor 21 Gene Transcription by Increasing the Expression of Activating Transcription Factor 4.

Authors:  Kimberly M Alonge; Gordon P Meares; F Bradley Hillgartner
Journal:  J Biol Chem       Date:  2017-02-10       Impact factor: 5.157

Review 4.  Insulinotropic Effects of Whey: Mechanisms of Action, Recent Clinical Trials, and Clinical Applications.

Authors:  Rachel L Adams; Kenneth Shane Broughton
Journal:  Ann Nutr Metab       Date:  2016-08-17       Impact factor: 3.374

5.  Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity.

Authors:  Fredirick L Mashili; Reginald L Austin; Atul S Deshmukh; Tomas Fritz; Kenneth Caidahl; Katrin Bergdahl; Juleen R Zierath; Alexander V Chibalin; David E Moller; Alexei Kharitonenkov; Anna Krook
Journal:  Diabetes Metab Res Rev       Date:  2011-03       Impact factor: 4.876

6.  Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets.

Authors:  Ffolliott M Fisher; Patricia C Chui; Imad A Nasser; Yury Popov; Jeremy C Cunniff; Thomas Lundasen; Alexei Kharitonenkov; Detlef Schuppan; Jeffrey S Flier; Eleftheria Maratos-Flier
Journal:  Gastroenterology       Date:  2014-07-30       Impact factor: 22.682

7.  FGF21 is an Akt-regulated myokine.

Authors:  Yasuhiro Izumiya; Holly A Bina; Noriyuki Ouchi; Yuichi Akasaki; Alexei Kharitonenkov; Kenneth Walsh
Journal:  FEBS Lett       Date:  2008-10-21       Impact factor: 4.124

8.  Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis?

Authors:  A M Arafat; P Kaczmarek; M Skrzypski; E Pruszyńska-Oszmalek; P Kołodziejski; D Szczepankiewicz; M Sassek; T Wojciechowicz; B Wiedenmann; A F H Pfeiffer; K W Nowak; M Z Strowski
Journal:  Diabetologia       Date:  2012-12-22       Impact factor: 10.122

9.  Multiorgan insulin sensitivity in lean and obese subjects.

Authors:  Caterina Conte; Elisa Fabbrini; Marleen Kars; Bettina Mittendorfer; Bruce W Patterson; Samuel Klein
Journal:  Diabetes Care       Date:  2012-04-03       Impact factor: 19.112

10.  Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance.

Authors:  Alberto O Chavez; Marjorie Molina-Carrion; Muhammad A Abdul-Ghani; Franco Folli; Ralph A Defronzo; Devjit Tripathy
Journal:  Diabetes Care       Date:  2009-06-01       Impact factor: 19.112

View more
  18 in total

1.  Decreased adipose tissue oxygenation associates with insulin resistance in individuals with obesity.

Authors:  Vincenza Cifarelli; Scott C Beeman; Gordon I Smith; Jun Yoshino; Darya Morozov; Joseph W Beals; Brandon D Kayser; Jeramie D Watrous; Mohit Jain; Bruce W Patterson; Samuel Klein
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

Review 2.  Branched Chain Amino Acids in Metabolic Disease.

Authors:  Zoltan Arany; Michael Neinast
Journal:  Curr Diab Rep       Date:  2018-08-15       Impact factor: 4.810

3.  Branched Chain Amino Acids.

Authors:  Michael Neinast; Danielle Murashige; Zoltan Arany
Journal:  Annu Rev Physiol       Date:  2018-11-28       Impact factor: 19.318

4.  Increases in bioactive lipids accompany early metabolic changes associated with β-cell expansion in response to short-term high-fat diet.

Authors:  Maxim D Seferovic; Christine A Beamish; Rockann E Mosser; Shannon E Townsend; Kirk Pappan; Vincent Poitout; Kjersti M Aagaard; Maureen Gannon
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-08-14       Impact factor: 4.310

5.  3-Hydroxyisobutyrate, A Strong Marker of Insulin Resistance in Type 2 Diabetes and Obesity That Modulates White and Brown Adipocyte Metabolism.

Authors:  Mona S Nilsen; Regine Å Jersin; Arve Ulvik; André Madsen; Adrian McCann; Per-Arne Svensson; Maria K Svensson; Bjørn G Nedrebø; Oddrun A Gudbrandsen; Grethe S Tell; C R Kahn; Per M Ueland; Gunnar Mellgren; Simon N Dankel
Journal:  Diabetes       Date:  2020-06-25       Impact factor: 9.461

6.  Repletion of branched chain amino acids reverses mTORC1 signaling but not improved metabolism during dietary protein dilution.

Authors:  Adriano Maida; Jessica S K Chan; Kim A Sjøberg; Annika Zota; Dieter Schmoll; Bente Kiens; Stephan Herzig; Adam J Rose
Journal:  Mol Metab       Date:  2017-06-24       Impact factor: 7.422

Review 7.  Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application.

Authors:  Dicky Struik; Marleen B Dommerholt; Johan W Jonker
Journal:  Curr Opin Lipidol       Date:  2019-06       Impact factor: 4.776

8.  Whole-body metabolic fate of branched-chain amino acids.

Authors:  Megan C Blair; Michael D Neinast; Zoltan Arany
Journal:  Biochem J       Date:  2021-02-26       Impact factor: 3.766

9.  Vegetarian diet, change in dietary patterns, and diabetes risk: a prospective study.

Authors:  Tina H T Chiu; Wen-Harn Pan; Ming-Nan Lin; Chin-Lon Lin
Journal:  Nutr Diabetes       Date:  2018-03-09       Impact factor: 5.097

10.  Higher Concentrations of BCAAs and 3-HIB Are Associated with Insulin Resistance in the Transition from Gestational Diabetes to Type 2 Diabetes.

Authors:  Ulrika Andersson-Hall; Carolina Gustavsson; Anders Pedersen; Daniel Malmodin; Louise Joelsson; Agneta Holmäng
Journal:  J Diabetes Res       Date:  2018-06-05       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.